Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
about
Cryptococcus gattii infectionsCurrent trends in the prevalence of Cryptococcus gattii in the United States and CanadaFluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine CryptococcosisMulticenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.Management of Cryptococcus gattii meningoencephalitis.Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolatesThe epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital.Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa.Phenotypic differences of Cryptococcus molecular types and their implications for virulence in a Drosophila model of infection.Isavuconazole: A New Option for the Management of Invasive Fungal Infections.Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010Geographically structured populations of Cryptococcus neoformans Variety grubii in Asia correlate with HIV status and show a clonal population structure.Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal studyGenome-Wide Transcription Study of Cryptococcus neoformans H99 Clinical Strain versus Environmental Strains.MLST and Whole-Genome-Based Population Analysis of Cryptococcus gattii VGIII Links Clinical, Veterinary and Environmental Strains, and Reveals Divergent Serotype Specific Sub-populations and Distant Ancestors.Identification and Characterization of VNI/VNII and Novel VNII/VNIV Hybrids and Impact of Hybridization on Virulence and Antifungal Susceptibility Within the C. neoformans/C. gattii Species ComplexIncreased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.ANTIFUNGAL SUSCEPTIBILITY TESTING AND GENOTYPING CHARACTERIZATION OF Cryptococcus neoformans AND gattii ISOLATES FROM HIV-INFECTED PATIENTS OF RIBEIRÃO PRETO, SÃO PAULO, BRAZIL.First environmental isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review.Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection.Primary cutaneous cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type VGI in Brazil: a case report and review of literature.Cryptococcus and cryptococcosis in Cuba. A minireview.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates.Cryptococcal meningitis due to Cryptococcus neoformans genotype AFLP1/VNI in Iran: a review of the literature.Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China.Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration.Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal SusceptibilityMolecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.Environmental isolation, biochemical identification, and antifungal drug susceptibility of Cryptococcus species.Immunoproteomics and immunoinformatics analysis of Cryptococcus gattii: novel candidate antigens for diagnosis.
P2860
Q27002687-21FDD70B-99A1-4ED9-9F80-962C168D2992Q28080670-00602AF1-F1E8-40BF-B9EC-60A0ADAA1AF5Q28544939-84022A7E-E05C-4052-88E0-08FEC0FA07D0Q30797685-4CEE6772-6091-42F9-BBE6-704447C510A6Q30873978-EA3C39B0-9BA5-4AF5-968E-907D03FB9D95Q30938136-C61988BB-F444-4572-9183-F0FA915D3872Q31138137-FCEF967A-30A8-4D24-B5DA-60608FC86E39Q33583425-C1014A07-7AB0-449D-8A46-FAC76286859DQ33703525-5F46AEE8-11CB-4B48-962F-37A63311ED05Q33703545-D342C77E-EF32-48DF-BC4D-47D9F84A661EQ33899747-6BBAF94E-0633-4077-BC80-08C5610F77B0Q34474946-D3C4613D-94B9-4E40-B703-1495E6DC7010Q34685419-4CDADB92-EA92-4E81-8887-B849A29E0EC7Q34982672-790AF360-4D98-4B9C-9672-4C71DD2E92C0Q35700772-A89EB9FD-232C-4A24-97BF-8A3EB2C04264Q35770474-E47AACAC-B6D4-448A-9C65-172213CB754AQ36095849-D6A5F46D-8FC0-43D2-AC8B-C7AA5A7D60AFQ36168992-55B23674-EB56-41EB-BEEF-E3CB27D9359DQ36290696-F6BC246A-CE45-4776-890C-3711409913ABQ36644733-FE44D083-9E95-4DBC-96AA-18424D72980CQ37026726-A96CCDF8-1F19-4002-958E-25EA4A3F434EQ37125086-8B1DABF0-034C-4190-AE10-9903152C6C6FQ37307916-13CD2361-330B-4C6E-BBF6-1AC78BDDF621Q38075599-0AE2A1C5-2ED6-4CDE-8B6D-756A8E5A63B7Q38154164-110F013C-AA21-472B-8A3A-F1A74DD5C5B8Q38165199-287061CC-D9F3-4C0A-9E4B-121CB694085AQ38194632-0E492661-CC3F-42F8-81A3-5AC5AAB05BF2Q38270904-C6AD1FBA-9483-4575-9050-1687AF2F5D16Q38284461-F812BD42-725F-4620-BEDE-236ADCD74E14Q38467366-85CB7D53-5D88-4290-B24A-EAEA1118B654Q38601382-11795FAF-5E42-4ED6-B508-60636FC9A276Q38610744-72754DF2-B692-43E9-853B-3AFD6EDE4355Q38813173-D1907FE9-62D9-4119-8BDF-E3024B4BC54CQ38852907-8FE05E56-4902-42CB-B72A-581FA0EC00F6Q38871468-D23A8D59-383B-4A35-A3CE-82FAA128C0F0Q38959280-744BB437-BF45-4FB8-A79A-1F2A7F47C419Q39061501-E42C58C0-9BB0-4C45-8943-19E09D93A458Q39064815-F83C02F7-6556-4DE8-B32E-33C1D1DB090FQ39199543-1353B43D-FDA7-47AE-A53D-E021744688F8Q39444326-E3DB6980-E403-4FD8-8163-ADD98FEA1339
P2860
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cryptococcus neoformans-Crypto ...... osaconazole, and voriconazole.
@ast
Cryptococcus neoformans-Crypto ...... osaconazole, and voriconazole.
@en
type
label
Cryptococcus neoformans-Crypto ...... osaconazole, and voriconazole.
@ast
Cryptococcus neoformans-Crypto ...... osaconazole, and voriconazole.
@en
prefLabel
Cryptococcus neoformans-Crypto ...... osaconazole, and voriconazole.
@ast
Cryptococcus neoformans-Crypto ...... osaconazole, and voriconazole.
@en
P2093
P2860
P50
P356
P1476
Cryptococcus neoformans-Crypto ...... posaconazole, and voriconazole
@en
P2093
A Espinel-Ingroff
A Fothergill
C Lass-Flörl
G St-Germain
J Turnidge
L Ostrosky-Zeichner
P2860
P304
P356
10.1128/AAC.01115-12
P407
P577
2012-09-04T00:00:00Z